$300 Million Stock Offering Priced by Celldex at $29.00 Per Share
CLDX has more than doubled off its 52-week low of $14.4.
Summary
Celldex Therapeutics has priced its previously announced public offering of common stock, raising $300 million by selling 10,345,000 shares at $29.00 per share. This follows the company's announcement of a proposed offering earlier today and comes after highly positive Phase 2 data for its investigational drug barzolvolimab was presented on March 27. The offering provides a substantial capital infusion, representing approximately 14.4% of the company's current market capitalization, which will be crucial for funding ongoing clinical trials and pipeline development. While the capital raise strengthens the balance sheet, it also results in material dilution for existing shareholders. Traders will be watching the market's reaction to the dilution versus the strategic capital infusion for pipeline advancement.
At the time of this announcement, CLDX was trading at $30.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $14.40 to $34.52. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.